|
|
|
| Advances in the Regulation of Receptor Tyrosine Kinase on Autophagy |
DONG Xue-ying1,2,LIANG Kai1,2,YE Ke-ying3,ZHOU Ce-fan1,2,**( ),TANG Jing-feng1,2,**() |
1 School of Food and Biological Engineering, Hubei University of Technology, Wuhan 430068, China
2 HBUT National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Hubei University of Technology, Wuhan 430068, China
3 Animal, Plant and Food Inspection and Quarantine Office, Chengdu Customs, Sichuan, Chengdu 610041, China |
|
|
|
Abstract Autophagy is a very conservative biological process of lysosomal degradation in eukaryotic evolution, which plays an important role in maintaining cell homeostasis and eliminating harmful components. Receptor tyrosine kinases (RTKs) are a class of kinase proteins that play an important role in the movement and invasion of normal cells and cancer cells. RTKs protein can not only promote autophagy, but also inhibit autophagy. Studies have shown that RTKs can play a regulatory role in tumors and related diseases through autophagy. For example, epidermal growth factor receptor (EGFR) can inhibit autophagy, thereby promoting tumor growth and proliferation; it can also pass RTK/Ras/ERK signaling pathways to induce autophagy, which in turn participates in related diseases such as cellular immune responses. The regulatory effects of RTKs on autophagy and related research results, which provide a basis for the theoretical basis of target targeted therapy were reviewed.
|
|
Received: 23 December 2020
Published: 01 June 2021
|
|
|
|
Corresponding Authors:
Ce-fan ZHOU,Jing-feng TANG
E-mail: cefan@whu.edu.com;tangjingfeng@hbut.edu.com
|
|
|
| [1] |
Ho C J, Gorski S M. Molecular mechanisms underlying autophagy-mediated treatment resistance in cancer. Cancers, 2019,11(11):1775.
doi: 10.3390/cancers11111775
|
|
|
| [2] |
Noda N N, Fujioka Y. Atg1 family kinases in autophagy initiation. Cellular and Molecular Life Sciences, 2015,72(16):3083-3096.
doi: 10.1007/s00018-015-1917-z
|
|
|
| [3] |
Amaya C, Fader C M, Colombo M I. Autophagy and proteins involved in vesicular trafficking. FEBS Letters, 2015,589(22):3343-3353.
doi: 10.1016/j.febslet.2015.09.021
|
|
|
| [4] |
Itakura E, Mizushima N. Characterization of autophagosome formation site by a hierarchical analysis of mammalian Atg proteins. Autophagy, 2010,6(6):764-776.
pmid: 20639694
|
|
|
| [5] |
Xie Z P, Nair U, Klionsky D J. Atg8 controls phagophore expansion during autophagosome formation. Molecular Biology of the Cell, 2008,19(8):3290-3298.
doi: 10.1091/mbc.e07-12-1292
|
|
|
| [6] |
Reggiori F, Tooze S A. Autophagy regulation through Atg9 traffic. Journal of Cell Biology, 2012,198(2):151-153.
|
|
|
| [7] |
Lemmon M A, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell, 2010,141(7):1117-1134.
doi: 10.1016/j.cell.2010.06.011
pmid: 20602996
|
|
|
| [8] |
Trenker R, Jura N. Receptor tyrosine kinase activation: From the ligand perspective. Current Opinion in Cell Biology, 2020,63:174-185.
doi: 10.1016/j.ceb.2020.01.016
|
|
|
| [9] |
Fraser J, Cabodevilla A G, Simpson J, et al. Interplay of autophagy, receptor tyrosine kinase signalling and endocytic trafficking. Essays in Biochemistry, 2017,61(6):597-607.
doi: 10.1042/EBC20170091
pmid: 29233871
|
|
|
| [10] |
Lampada A, Hochhauser D, Salomoni P. Autophagy and receptor tyrosine kinase signalling: a mTORC2 matter. Cell Cycle, 2017,16(20):1855-1856.
doi: 10.1080/15384101.2017.1372548
|
|
|
| [11] |
Chukkapalli S, Amessou M, Dilly A K, et al. Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cells. Experimental Cell Research, 2014,320(2):233-246.
doi: 10.1016/j.yexcr.2013.10.022
pmid: 24211352
|
|
|
| [12] |
Kandouz M, Haidara K, Zhao J, et al. The EphB2 tumor suppressor induces autophagic cell death via concomitant activation of the ERK1/2 and PI3K pathways. Cell Cycle, 2010,9(2):398-407.
doi: 10.4161/cc.9.2.10505
|
|
|
| [13] |
Tanabe H, Kuribayashi K, Tsuji N, et al. Sesamin induces autophagy in colon cancer cells by reducing tyrosine phosphorylation of EphA1 and EphB2. International Journal of Oncology, 2011,39(1):33-40.
|
|
|
| [14] |
Zhong S Z, Pei D, Shi L, et al. Ephrin-B2 inhibits Aβ25-35-induced apoptosis by alleviating endoplasmic reticulum stress and promoting autophagy in HT22 cells. Neuroscience Letters, 2019,704:50-56.
doi: 10.1016/j.neulet.2019.03.028
|
|
|
| [15] |
Singh R, Karri D, Shen H, et al. TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis. The Journal of Clinical Investigation, 2018,128(7):3129-3143.
doi: 10.1172/JCI96060
|
|
|
| [16] |
Molloy N H, Read D E, Gorman A M. Nerve growth factor in cancer cell death and survival. Cancers, 2011,3(1):510-530.
doi: 10.3390/cancers3010510
pmid: 24212627
|
|
|
| [17] |
Dadakhujaev S, Jung E J, Noh H S, et al. Interplay between autophagy and apoptosis in TrkA-induced cell death. Autophagy, 2009,5(1):103-105.
doi: 10.4161/auto.5.1.7276
|
|
|
| [18] |
Dadakhujaev S, Noh H S, Jung E J, et al. The reduced catalase expression in TrkA-induced cells leads to autophagic cell death via ROS accumulation. Experimental Cell Research, 2008,314(17):3094-3106.
doi: 10.1016/j.yexcr.2008.08.013
|
|
|
| [19] |
Koorstra J B M, Karikari C, Feldmann G, et al. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biology & Therapy, 2009,8(7):618-626.
|
|
|
| [20] |
Colavito S A. AXL as a target in breast cancer therapy. Journal of Oncology, 2020,2020:5291952.
|
|
|
| [21] |
Neubauer A, O’Bryan J P, Fiebeler A, et al. Axl, a novel receptor tyrosine kinase isolated from chronic myelogenous leukemia. Seminars in Hematology, 1993,30(3 Suppl 3):34.
|
|
|
| [22] |
Paccez J D, Vogelsang M, Parker M I, et al. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. International Journal of Cancer, 2014,134(5):1024-1033.
doi: 10.1002/ijc.v134.5
|
|
|
| [23] |
Holland S J, Pan A, Franci C, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Research, 2010,70(4):1544-1554.
doi: 10.1158/0008-5472.CAN-09-2997
pmid: 20145120
|
|
|
| [24] |
Vajkoczy P, Knyazev P, Kunkel A, et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proceedings of the National Academy of Sciences of the United States of America, 2006,103(15):5799-5804.
|
|
|
| [25] |
Han J, Bae J, Choi C Y, et al. Autophagy induced by AXL receptor tyrosine kinase alleviates acute liver injury via inhibition of NLRP3 inflammasome activation in mice. Autophagy, 2016,12(12):2326-2343.
doi: 10.1080/15548627.2016.1235124
|
|
|
| [26] |
Lee C H, Chun T. Anti-inflammatory role of TAM family of receptor tyrosine kinases via modulating macrophage function. Molecules and Cells, 2019,42(1):1-7.
|
|
|
| [27] |
Han W D, Pan H M, Chen Y, et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One, 2011,6(6):e18691.
doi: 10.1371/journal.pone.0018691
|
|
|
| [28] |
Wei Y J, Zou Z J, Becker N, et al. EGFR-mediated beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell, 2013,154(6):1269-1284.
doi: 10.1016/j.cell.2013.08.015
|
|
|
| [29] |
So K S, Kim C H, Rho J K, et al. Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M. PLoS One, 2014,9(12):e114000.
doi: 10.1371/journal.pone.0114000
|
|
|
| [30] |
Wang R C, Wei Y, An Z, et al. Akt-mediated regulation of autophagy and tumorigenesis through beclin 1 phosphorylation. Science, 2012,338(6109):956-959.
doi: 10.1126/science.1225967
|
|
|
| [31] |
Kwon Y, Kim M, Jung H S, et al. Targeting autophagy for overcoming resistance to anti-EGFR treatments. Cancers, 2019,11(9):1374.
doi: 10.3390/cancers11091374
|
|
|
| [32] |
Domigan C K, Warren C M, Antanesian V, et al. Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy. Journal of Cell Science, 2015,128(12):2236-2248.
doi: 10.1242/jcs.163774
|
|
|
| [33] |
Lee S, Chen T T, Barber C L, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell, 2007,130(4):691-703.
doi: 10.1016/j.cell.2007.06.054
|
|
|
| [34] |
Warr M R, Binnewies M, Flach J, et al. FOXO3A directs a protective autophagy program in haematopoietic stem cells. Nature, 2013,494(7437):323-327.
doi: 10.1038/nature11895
|
|
|
| [35] |
Spengler K, Kryeziu N, Groβe S, et al. VEGF triggers transient induction of autophagy in endothelial cells via AMPKα1. Cells, 2020,9(3):687.
doi: 10.3390/cells9030687
|
|
|
| [36] |
Chen C H, Liu Y M, Pan S L, et al. Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo. Oncotarget, 2016,7(18):26374-26387.
doi: 10.18632/oncotarget.v7i18
|
|
|
| [37] |
Dieci M V, Arnedos M, Andre F, et al. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discovery, 2013,3(3):264-279.
doi: 10.1158/2159-8290.CD-12-0362
|
|
|
| [38] |
Du Z F, Lovly C M. Mechanisms of receptor tyrosine kinase activation in cancer. Molecular Cancer, 2018,17(1):1-13.
doi: 10.1186/s12943-017-0753-1
|
|
|
| [39] |
Lampada A, O’Prey J, Szabadkai G, et al. mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism. Cell Death & Differentiation, 2017,24(6):1045-1062.
|
|
|
| [40] |
Wu M, Zhang P H. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance. Cancer Letters, 2020,469:207-216.
doi: 10.1016/j.canlet.2019.10.030
|
|
|
| [41] |
Zhou C F, Qian X H, Hu M, et al. STYK1 promotes autophagy through enhancing the assembly of autophagy-specific class III phosphatidylinositol 3-kinase complex I. Autophagy, 2020,16(10):1786-1806.
doi: 10.1080/15548627.2019.1687212
|
|
|
| [42] |
Huang Z, Ma N, Xiong Y L, et al. Aberrantly high expression of NOK/STYK1 is tightly associated with the activation of the AKT/GSK3β/N-cadherin pathway in non-small cell lung cancer. OncoTargets and Therapy, 2019,12:10299-10309.
doi: 10.2147/OTT.S210014
pmid: 31819514
|
|
|
| [43] |
Meng X R, Wang H J, Zhao J Z, et al. Apatinib inhibits cell proliferation and induces autophagy in human papillary thyroid carcinoma via the PI3K/Akt/mTOR signaling pathway. Frontiers in Oncology, 2020,10:217.
doi: 10.3389/fonc.2020.00217
|
|
|
| [44] |
Tao J Y, Sun D T, Hou H L. Role of YES1 amplification in EGFR mutation-positive non-small cell lung cancer: Primary resistance to afatinib in a patient. Thoracic Cancer, 2020,11(9):2736-2739.
doi: 10.1111/tca.v11.9
|
|
|
| [45] |
Curry D W, Stutz B, Andrews Z B, et al. Targeting AMPK signaling as a neuroprotective strategy in Parkinson’s disease. Journal of Parkinson’s Disease, 2018,8(2):161-181.
|
|
|
| [46] |
Vernizzi L, Paiardi C, Licata G, et al. Glutamine synthetase 1 increases autophagy lysosomal degradation of mutant huntingtin aggregates in neurons, ameliorating motility in a Drosophila model for Huntington’s disease. Cells, 2020,9(1):196.
doi: 10.3390/cells9010196
|
|
|
| [47] |
Forloni G, Balducci C. Alzheimer’s disease, oligomers, and inflammation. Journal of Alzheimer’s Disease, 2018,62(3):1261-1276.
|
|
|
| [48] |
Sun B L, Li W W, Zhu C, et al. Clinical research on Alzheimer’s disease: progress and perspectives. Neuroscience Bulletin, 2018,34(6):1111-1118.
doi: 10.1007/s12264-018-0249-z
|
|
|
| [49] |
Zou L, Wang Z, Shen L, et al. Receptor tyrosine kinases positively regulate BACE activity and Amyloid-beta production through enhancing BACE internalization. Cell Research, 2007,17(5):389-401.
doi: 10.1038/cr.2007.5
|
|
|
| [50] |
Frisardi V, Santamato A, Cheeran B. Parkinson’s disease: new insights into pathophysiology and rehabilitative approaches. Parkinson’s Disease, 2016,2016:1-2.
|
|
|
| [51] |
Chittoor-Vinod V G, Villalobos-Cantor S, Roshak H, et al. Dietary amino acids impact LRRK2-induced neurodegeneration in Parkinson’s disease models. The Journal of Neuroscience, 2020,40(32):6234-6249.
doi: 10.1523/JNEUROSCI.2809-19.2020
|
|
|
| [52] |
Valionyte E, Yang Y, Roberts S L, et al. Lowering mutant huntingtin levels and toxicity: autophagy-endolysosome pathways in Huntington’s disease. Journal of Molecular Biology, 2020,432(8):2673-2691.
doi: S0022-2836(19)30677-1
pmid: 31786267
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
